- Home
- DJT vs APLS Comparison
DJT vs APLS Comparison
Compare DJT & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJT | APLS |
|---|---|---|
| Founded | 2021 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | DJT | APLS |
|---|---|---|
| Price | $9.82 | $18.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $31.85 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.97 |
| P/E Ratio | ★ N/A | $94.75 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $9.72 | $16.10 |
| 52 Week High | $27.29 | $30.48 |
Technical Indicators
Market Signals| Indicator | DJT | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 32.61 |
| Support Level | N/A | $17.16 |
| Resistance Level | $11.65 | $20.42 |
| Average True Range (ATR) | 0.47 | 0.80 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 6.14 | 12.90 |
Price Performance
Historical ComparisonAbout DJT Trump Media & Technology Group Corp.
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.